整合基因组与转录组分析揭示血管免疫母细胞性T细胞淋巴瘤的可靶向脆弱性
本研究对血管免疫母细胞性T细胞淋巴瘤(AITL)进行全外显子组、转录组和甲基化分析,发现TET2、DNMT3A、IDH2 R172等表观遗传驱动基因及TET3、KMT2D等新突变,TET2/IDH2 R172/DNMT3A共突变者预后差(p<0.0001),CD28突变/融合与不良预后相关(p=0.02),并揭示PI3K通路异常及PHLPP2低表达预测不良预后(p=0.05),为临床试验提供治疗靶点。
要点
- TET2、IDH2 R172、DNMT3A共突变AITL预后差(p<0.0001)。
- CD28突变/融合与不良预后相关(p=0.02)。
- 低PHLPP2 mRNA表达预测不良预后(p=0.05),PHLPP2或TET2缺失增强PI3K活化。
核心结论
- AITL存在TET2、DNMT3A、IDH2 R172等表观遗传驱动突变及CD28、PLCG1等TCR信号相关突变,TET2/IDH2 R172/DNMT3A共突变和CD28突变/融合与不良预后相关,低PHLPP2 mRNA表达预测不良预后,PI3K通路激活为潜在治疗靶点。
研究设计与样本
- 研究采用全外显子组测序(n=124)、转录组分析(n=78)和甲基化分析(n=40)对AITL样本进行整合分析。
- 对纯化的肿瘤性T细胞(CD3+PD1+)进行全外显子组测序,并与全肿瘤活检样本比对。
- 对12例AITL患者来源的异种移植模型(PDX)进行RNA-seq和全外显子组测序分析。
主要发现
- TET2、IDH2 R172、DNMT3A共突变的AITL预后差(p<0.0001)。
- CD28突变/融合与不良预后相关(p=0.02)。
- RNA-seq分析发现调节TCR活化的融合转录本(8%),TCR库受限(α=87%,β=72%),并存在Epstein-Barr病毒转录组(73%)。
- 基因表达谱显示肿瘤微环境中B细胞或树突状细胞与预后相关(p<0.01)。
- 低PHLPP2 mRNA表达预测不良预后(p=0.05)。
关键数值与推荐
- TET2、IDH2 R172、DNMT3A共突变AITL预后差(p<0.0001)。
- CD28突变/融合与不良预后相关(p=0.02)。
- 低PHLPP2 mRNA表达预测不良预后(p=0.05)。
- RNA-seq分析显示融合转录本调节TCR活化(8%),TCR库受限(α=87%,β=72%),Epstein-Barr病毒转录组存在(73%)。
- 基因表达谱显示肿瘤微环境中B细胞或树突状细胞与预后相关(p<0.01)。
临床怎么用
- 工程化PHLPP2或TET2缺失的CD4+ T细胞显示PI(3)K活化增强,揭示了一个临床试验的治疗靶点。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Nodal follicular helper T-cell (T FH) lymphoma of the angioimmunoblastic (AITL) subtype has a dismal prognosis. Using whole-exome sequencing (n = 124), transcriptomic (n = 78), and methylation (n = 40) analysis, we identified recurrent mutations in known epigenetic drivers (TET2, DNMT3A, IDH2 R172 ) and novel ones (TET3, KMT2D). TET2, IDH2 R172 , DNMT3A co-mutated AITLs had poor prognosis (p < 0.0001). Genes regulating T-cell receptor (TCR) signaling (CD28, PLCG1, VAV1, FYN) or activation (RHOA G17V ) or regulators of the PI3K-pathway (PIK(3)C members, PTEN, PHLPP1, PHLPP2) were mutated. CD28 mutation/fusion was associated with poor prognosis (p = 0.02). WES of purified, neoplastic T-cell (CD3+PD1+) demonstrated high concordance with whole tumor biopsies and validated the presence of TET2 and DNMT3A in tumor and non-lymphoid cells, but other mutations (CD28, RHOA G17V , IDH2 R172 , PLCG1) in neoplastic cells. Integrated DNA-methylation and mRNA expression analysis revealed epigenetic alterations in genes regulating TCR, cytokines, PI3K-signaling, and apoptosis. RNA-seq analysis identified fusion transcripts regulating TCR-activation (8%), revealed a restricted TCR-repertoire (α = 87%, β = 72%), and showed the presence of Epstein-Barr virus transcriptome (73%). GEP demonstrated the association of B-cells or dendritic cells in the tumor milieu with prognosis (p < 0.01). RNA-seq and WES analysis of 12 AITL-patient-derived-xenografts (PDX) showed that bi-allelic TET2 and DNMT3A mutations or sub-clonal mutations (PLCG1, PHLPP2) propagated in sequential passages, and gene signatures related to T FH and T CM (central-memory) were well-maintained through passages. Gene expression signatures associated with late PDX passages (3rd-5th) were enriched with proliferation and metabolic reprogramming-related genes and predicted prognosis in an independent AITL series. Low PHLPP2 mRNA expression predicted poor prognosis (p = 0.05) and engineered PHLPP2 or TET2 loss in CD4+ T-cells showed enhanced PI(3)K activation, thus uncovering a therapeutic target for clinical trials.
引用
- Bouska A, Zhang W, Sharma S, et al. Integrative Genomic and Transcriptomic Analysis Reveals Targetable Vulnerabilities in Angioimmunoblastic T-Cell Lymphoma. Am J Hematol. 2025. PMID: 40510016. doi:10.1002/ajh.27736
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。